Skip to main content

Rosetta Genomics, NYU Add Neonatal Heart Disorder to miRNA Cancer Alliance

NEW YORK (GenomeWeb News) — Rosetta Genomics has added congenital neonatal cardiovascular disease to a collaboration with the New York University School of Medicine that was originally created to use miRNA technology to develop cancer diagnostics, the company said today.
Rehovot, Israel-based Rosetta Genomics said the research will screen for specific miRNA biomarkers and signatures that could help diagnose or target congenital heart disease in newborns.
Around 40,000, or one out of every 125, US infants are born with CHD, which is caused by the improper development of vessels near the heart, the company said.
"It is now clear that microRNAs play a key role in controlling diverse aspects of cardiac development and response to disease," David Meyer, director of the Pediatric and Congenital Cardiothoracic Surgery at NYU, said in a statement.
“Recent studies have revealed key roles of microRNAs as regulators of growth, development, function, and responses to stress in the heart,” Rosetta Genomics said, adding that these “regulatory mechanisms may serve as potential diagnostic biomarkers and therapeutic targets for the treatment of heart disease.”
Financial terms of the expanded agreement were not released.
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.